Janssen Vaccines & Prevention B.v.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Beth Israel Deaconess Medical Center, Inc.

Janssen Pharmaceuticals, Inc.

Bavarian Nordic A/s

Macaya Julie Douoguih

Dan H Barouch

Jerald C Sadoff

Robin Steigerwald

Benoit Christophe Stephan Callendret

Ulrike Dirmeier

Ariane Volkmann

Lucy A Ward

Gaston Rafael Picchio

Olivier Godeaux

Compositions, vaccines and methods using adenovirus vectors for inducing protective immunity against a respiratory syncytial virus (RSV) infection are described.

Methods and compositions for inducing protective immunity against RSV infection

Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.

Method of providing safe administration of adenoviral vectors encoding a zika virus antigen

Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response. The compositions and methods can be used to provide a protective immunity against a disease, such as an infection of one or more subtypes of Ebola and Marburg filoviruses, in humans.

Methods and compositions for enhancing immune responses

Growing community of inventors

Reston, VA, United States of America

Macaya Julie Douoguih